Comparison of the indirect immunofluorescence assay and a commercial ELISA to detect KSHV antibodies
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.01186-24 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Valentin Leducq und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virolo…. Hauptthemen laut MEDLINE: Herpesvirus 8, Human, Enzyme-Linked Immunosorbent Assay, Antibodies, Viral, Sensitivity and Specificity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kaposi’s sarcoma-associated herpesvirus (KSHV) is an oncogenic virus involved in several diseases. The gold standard for KSHV sero diagnosis remains the indirect immunofluorescence assay (IFA), which is time-consuming and operator-dependent. We compared this method with an enzyme-linked immunosorbent assay (ELISA) targeting solubilized KSHV whole-genome extract among positive ( n = 49, including 76% of HIV-infected patients) and negative ( n = 14) control groups. We also included 14 sera with equivocal IFA results. ELISA showed better performance in detecting KSHV antibodies (McNemar’s test, P = 0.0455). The sensitivity and specificity of both methods were 79% (64–89) and 100% (66–100) for the IFA, respectively, and 94% (83–99) and 100% (66–100) for ELISA, respectively. All IFA equivocal results were either negative or positive with ELISA. ELISA is more reliable and could be a good alternative for determining KSHV serological status, particularly in the context of immunocompromised patients and equivocal serology with the IFA. IMPORTANCE Kaposi’s sarcoma-associated herpesvirus (KSHV) sero status remains challenging because no perfect reference is available for the detection of KSHV antibodies. The current gold-standard method, the indirect immunofluorescence assay (IFA), has a very good specificity of close to 100%, but a lower sensitivity of around 80–85%, which decreases to 64–67% in immunocompromised patients. Additionally, this method is time-consuming and operator-dependent compared with new serological assays such as the enzyme-linked immunosorbent assay (ELISA). Thus, further research is still needed to improve KSHV sero diagnosis. Here, we compare the KSHV IgG ELISA kit assay (Advanced Biotechnologies Inc) with the gold-standard IFA, targeting the LANA-1 protein from latent BC-3 cell lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France.
ORCID-Profile: Aude Jary
Zitieren
APA
Leducq, V., Ben Said, L., Sayon, S., Calvez, V., Marcelin, A. G., & Jary, A. (2024). Comparison of the indirect immunofluorescence assay and a commercial ELISA to detect KSHV antibodies. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01186-24
Vancouver
Leducq V, Ben Said L, Sayon S, Calvez V, Marcelin AG, Jary A. Comparison of the indirect immunofluorescence assay and a commercial ELISA to detect KSHV antibodies. Microbiology Spectrum. 2024. doi:10.1128/spectrum.01186-24
BibTeX
@article{Leducq2024,
author = {Leducq, Valentin and Ben Said, Léa and Sayon, Sophie and Calvez, Vincent and Marcelin, Anne-Geneviève and Jary, Aude},
title = {Comparison of the indirect immunofluorescence assay and a commercial ELISA to detect KSHV antibodies},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.01186-24}
}
EUVIMED